NEW YORK (GenomeWeb News) – Invitrogen today said that it had non-exclusively licensed its patents covering the random prime amplification of nucleic acids to Qiagen, New England Biolabs, and Kirkegaard & Perry Laboratories.
 
The patents cover methods and kits used for “substantially” amplifying nucleic acids, Invitrogen said. The technology is used in common lab techniques, such as random prime labeling reactions, first-strand cDNA synthesis, and whole genome amplification.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.